Loading news...
Profitability This table compares Arch Therapeutics and SANUWAVE Health's net margins, return on equity and return on assets. Net Margins Return on Equity Return on Assets Arch Therapeutics -8,257.70% N/A -730.22% SANUWAVE Health -1.33% -23.83% -20.60% Institutional and Insider Ownership 6.9% of Arch Therapeutics shares are held by institutional investors. Comparatively, 42.5% of SANUWAVE Health
Sanuwave Health Reports Preliminary Q4 2025 Revenue of $13.3–$13.4 Million, Up 29–30% Year-over-Year; Achieves Record Quarterly and Full-Year Revenue
InfuSystem (NYSE: INFU - Get Free Report) and SANUWAVE Health (OTCMKTS:SNWV - Get Free Report) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their valuation, earnings, risk, profitability, analyst recommendations, institutional ownership and dividends. Analyst Ratings This is a breakdown of recent
Valuation and Earnings This table compares SANUWAVE Health and Carmell"s revenue, earnings per share (EPS) and valuation. Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio SANUWAVE Health $41.28 million 6.55 -$25.81 million ($1.30) -24.24 Carmell $32,839.00 343.12 -$15.44 million ($0.46) -1.17 Carmell has lower revenue, but higher earnings than SANUWAVE Health. SANUWAVE
AWM Investment Company Inc. reduced its position in Sanuwave Health Inc. (NASDAQ: SNWV) by 4.6% in the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 489,550 shares of the company's stock after selling 23,680 shares during the period. Sanuwave Health comprises
EDEN PRAIRIE, Minn. , Dec. 10, 2025 (GLOBE NEWSWIRE) -- Sanuwave Health, Inc. (the "Company" or "Sanuwave") (NASDAQ: SNWV), a leading provider of FDA-approved next-generation wound care products, is pleased to announce that it will be attending the upcoming 44th Annual J.
Healogics Wound Care Supply adds UltraMIST to its Group Purchasing Organization Healogics iSupply and Sanuwave collaborate to provide UltraMIST as an option for GPO members EDEN PRAIRIE, Minn., Dec. 08, 2025 (GLOBE NEWSWIRE) -- Sanuwave Health, Inc. (the "Company" or "Sanuwave”) (NASDAQ: SNWV), a leading provider of next-generation FDA-approved wound care products, is pleased to announce the addition of its UltraMIST product line to Healogics iSupply.
Profitability This table compares SANUWAVE Health and Acutus Medical's net margins, return on equity and return on assets. Net Margins Return on Equity Return on Assets SANUWAVE Health -1.33% -23.83% -20.60% Acutus Medical -272.74% -311.64% -11.57% Volatility and Risk SANUWAVE Health has a beta of 1.22, suggesting that its share price is 22% more volatile
SANUWAVE Health, Inc. ( SNWV ) Q3 2025 Earnings Call November 7, 2025 8:30 AM EST Company Participants Morgan Frank - CEO & Chairman Peter Sorensen - CFO & Secretary Conference Call Participants Ian Cassel - Intelligent Fanatics Capital Management Llc Kyle Bauser - ROTH Capital Partners, LLC, Research Division Carl Byrnes - Northland Capital Markets, Research Division Alex Silverman - AWM Investment Company Inc Andrew Rem Presentation Operator Good day, everyone, and welcome to the SANUWAVE earnings call. [Operator Instructions] Please note, this call may be recorded.
Sanuwave Health Inc. (SNWV) came out with quarterly earnings of $0.46 per share, beating the Zacks Consensus Estimate of $0.32 per share. This compares to a loss of $6.49 per share a year ago.
Q3 2025 revenues were $11.5 million , up 22% from $9.4 million in Q3 2024. This represents the highest quarterly revenues in Company history.
EDEN PRAIRIE, Minn., Nov. 03, 2025 (GLOBE NEWSWIRE) -- Sanuwave Health, Inc. (the "Company" or "Sanuwave”) (NASDAQ: SNWV), a leading provider of next-generation FDA-approved wound care products, will host a live conference call on Friday, November 7, 2025, at 8:30 AM (ET) to present its Q3 2025 financial results.
Sanuwave Health (SNWV) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Institutional and Insider Ownership 42.5% of SANUWAVE Health shares are held by institutional investors. 14.9% of SANUWAVE Health shares are held by insiders. Comparatively, 5.2% of H-CYTE shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the
U.S. stock futures were slightly higher this morning, with the Dow futures gaining around 0.1% on Tuesday.
Sanuwave Health (SNWV) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock suggests that there could be more strength down the road.
SANUWAVE Health, Inc. (NASDAQ:SNWV ) Q3 2025 Earnings Call October 6, 2025 5:30 PM EDT Company Participants Morgan Frank - CEO & Chairman Conference Call Participants Kyle Bauser - ROTH Capital Partners, LLC, Research Division Carl Byrnes - Northland Capital Markets, Research Division Presentation Operator Good day, everyone, and welcome to the SANUWAVE Q3 Revenue Update. [Operator Instructions] Please note today's call will be recorded.
Sanuwave announces preliminary revenues of $11.4 million to $11.6 million for the third quarter ended September 30, 2025. This represents the highest quarterly revenues in Company history.
The global healthcare market is growing rapidly—it is expected to climb at a 6.9% CAGR over the next eight years, reaching more than $22.3 trillion by 2033. Its appeal to investors in the current market environment may also lie in its non-cyclical nature, thanks to resilient demand that is more related to health needs and demographics than to external economic conditions.
Credit facility from J.P. Morgan consists of a four-year term loan of $23 million and a two-year $5 million revolving credit facility backed by accounts receivable Both the term loan and revolver have an interest rate of SOFR +350bp The Company drew approximately $1 million from the revolver at commencement, resulting in total outstanding debt under the new facility of approximately $24 million.